Bloomberg News

OncoMed Jumps After Signing $177 Million Deal With Celgene (2)

December 03, 2013

OncoMed Pharmaceuticals Inc. (OMED:US), a drug developer that first sold shares to the public in July, almost doubled in trading after signing a $177.25 million agreement with Celgene Corp. (CELG:US) on as many as six potential cancer medicines.

OncoMed rose 98 percent to $27.70 at the close in New York in the biggest one-day rise since the company’s initial public offering. The shares of the Redwood City, California-based company have gained 63 percent since the IPO.

The deal includes a $22.25 million equity investment and additional payments tied to development and sales goals which may total more than $3 billion, the companies said today in a statement. OncoMed, whose drugs target cancer stem cells, will oversee early clinical studies, and Summit, New Jersey-based Celgene will then have the option to license worldwide rights to the compounds.

Celgene, the world’s fourth-largest biotechnology company, gets an exclusive option on OncoMed’s demcizumab, which is in early stage studies in diseases including pancreatic cancer. Celgene shares, which have doubled this year, declined 2 percent to $159.93.

OncoMed was advised by Latham & Watkins LLP and Leerink Swann LLC. The company also has partnerships with Bayer AG (BAYN) and GlaxoSmithKline Plc.

To contact the reporter on this story: Meg Tirrell in New York at mtirrell@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net


We Almost Lost the Nasdaq
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

Companies Mentioned

  • OMED
    (OncoMed Pharmaceuticals Inc)
    • $21.96 USD
    • 0.43
    • 1.96%
  • CELG
    (Celgene Corp)
    • $86.66 USD
    • 1.35
    • 1.56%
Market data is delayed at least 15 minutes.
 
blog comments powered by Disqus